1.18
+0(+0.00%)
Currency In USD
| Previous Close | 1.18 |
| Open | 1.18 |
| Day High | 1.19 |
| Day Low | 1.14 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.14 |
| Volume | 2.52M |
| Average Volume | 3.3M |
| Market Cap | 313.13M |
| PE | -14.75 |
| EPS | -0.08 |
| Moving Average 50 Days | 1.51 |
| Moving Average 200 Days | 2.6 |
| Change | 0 |
If you invested $1000 in Akebia Therapeutics, Inc. (AKBA) 10 years ago, it would be worth $153.25 as of February 21, 2026 at a share price of $1.18. Whereas If you bought $1000 worth of Akebia Therapeutics, Inc. (AKBA) shares 5 years ago, it would be worth $287.1 as of February 21, 2026 at a share price of $1.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
GlobeNewswire Inc.
Feb 19, 2026 1:00 PM GMT
Akebia to Host Conference Call on February 26 at 8:00 a.m. ESTCAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 1:00 PM GMT
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomerulosclerosis (FSGS) AKB-097 Phase 2 rare kidney